PRODUCT: MLN2480

ALTERNATE NAMES: ML-N2480; ML N2480; BIIB-024; BIIB024; BIIB 024; TAK-58; TAK580; TAK 580; AMG 2112819; AMG-2112819; AMG2112819; (R)-2-[(1R)-1-[(6-amino-5-chloropyrimidine-4-carboxamide)ethy]-N-(5-chloro-4-{trifluoromethyl}pyridin-2-yl)thiazole-5-carboxamide; 2-[(1R)-1-[(6-amino-5-chloropyrimidine-4-carboxyl)amino]ethyl]-N-(5-chloro-4-[trifluoromethyl]pyridin-2-yl)-1,3-thiazole-5-carboxamide

CATALOG#: B1706-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE: [Chemical structure image]

MOLECULAR FORMULA: C₁₇H₁₂Cl₂F₃N₇O₆S

MOLECULAR WEIGHT: 506.29

CAS NUMBER: 1096708-71-2

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: MLN 2480 (BIIB-024) is an oral, selective pan-Raf kinase inhibitor in clinical trials.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:
1. Elizabeth Grace Carideo Cunniff et al. Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC. Mol Cancer Ther November 2013 12; C146

RELATED PRODUCTS:
- B-Raf Inhibitor 1 (Cat#2599)
- CEP-32496 (Cat# 9615)
- DP-4978 (Cat# B1288)
- GSK-2118436 mesylate (Cat# 2800)
- PLX-7904 (Cat# B1249)
- PLX-4720 (Cat# 2813)
- Regorafenib (Cat# 2891)
- TAK-632 (Cat# 2473)

USAGE: FOR RESEARCH USE ONLY! Not to be used in humans

BioVision Incorporated
155 S. Milpitas Boulevard, Milpitas, CA 95035 USA
Tel: 408-493-1800 | Fax: 408-493-1801
www.biovision.com | tech@biovision.com